 Planning underway for a Phase 1 Trial to assess new immunotherapy aimed at stimulating the innate immune system to clear beta amyloid protein plaques in Alzheimers Disease SHANGHAI and GAITHERSBURG, Md. , July 30, 2021 PRNewswire -- I-Mab the Company Nasdaq: IMAB, a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the U.S. Food and Drug Administration FDA has cleared the Investigational New Drug IND submission for Protollin, an investigational drug to treat Alzheimers disease, enabling a Phase 1 clinical trial to be initiated. 